home / stock / htbx / htbx news

HTBX News and Press, Heat Biologics Inc. From 03/14/22

Stock Information
Company Name: Heat Biologics Inc.
Stock Symbol: HTBX
Market: NASDAQ
Website: heatbio.com
Menu
HTBX HTBX Quote HTBX Short HTBX News HTBX Articles HTBX Message Board
Get HTBX Alerts

News, Short Squeeze, Breakout and More Instantly...
HTBX - Heat Biologics reports 2021 revenue $2.1M, consensus $2.11M

Heat Biologics (NYSE:HTBX) has presented favorable survival data at The American Association of Cancer Research of HS-110 in combination with checkpoint inhibitors for the treatment of non-small cell lung cancer. Also, submitted meeting requests to the FDA for separate Type B and Type C meeti...
HTBX - DB, ING and HTBX among pre market gainers

Volt Information Sciences (NYSE:VOLT) +96% on acquisition proposal from ACS Solutions affiliate. Zhongchao (NASDAQ:ZCMD) +41%. Turquoise Hill Resources (NYSE:TRQ) +31% after receiving Rio Tinto's takeover proposal. Amphastar Pharmaceuticals (NASDAQ:AMPH) +24%. Mullen Autom...

HTBX - Heat Biologics Provides Year-End 2021 Business Update

DURHAM, N.C., March 14, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX) , a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today provided strategic, financial, ...

HTBX - Heat Biologics to move to NYSE from Nasdaq

Heat Biologics (NASDAQ:HTBX) said it plans to change its listing to the NYSE American stock exchange from from the Nasdaq Capital Market. Heat expects to begin trading on NYSE under its existing HTBX symbol when markets open on Feb. 14. The company will continue to trade o...
HTBX - Heat Biologics Announces Planned Transfer to the NYSE American

DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, announced today that it plans to change its listing from ...

HTBX - Elusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM®, Its Treatment for Inhalation Anthrax, to the U.S. Department of Health and Human Services

Completed first phase of contract for $50 million; HHS options to procure up to $31 million of ANTHIM by the first half of 2023 Reaffirms ANTHIM as an important medical countermeasure in the U.S. government’s strategy to maintain sufficient quantities of anthrax anti-toxin to e...

HTBX - When Heat Biologics Inc (HTBX) Moves Investors should Listen

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
HTBX - Heat Biologics Announces New PTX-35 Preclinical Data in Organ Transplantation and Provides Update on HS-110

DURHAM, N.C., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX) , a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced promising new preclinical dat...

HTBX - Heat Biologics Inc HTBX Pivot Points

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

HTBX - Trend Tracker for Heat Biologics Inc HTBX

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Previous 10 Next 10